BIOCON vs CAPLIPOINT: Stock Comparison

Biocon Limited vs Caplin Point Laboratories Limited

Live data: 22 July 2026, 2:59 PM IST • Source: NSE and company filings

Biocon Limited is the larger company by market capitalisation. Caplin Point Laboratories Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biocon Limited and Caplin Point Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOCON is more favourable on 1 of 13 scored metrics and CAPLIPOINT on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BIOCON is the larger company
₹70,989 Cr vs ₹18,839 Cr
P/E Ratio
CAPLIPOINT has a lower P/E
31.01x vs 185.25x
P/B Ratio
BIOCON has a lower P/B
2.1x vs 5.54x
EPS
CAPLIPOINT has higher earnings per share
₹83.98 vs ₹2.86
Dividend Yield
CAPLIPOINT has a higher dividend yield
0.3% vs 0.11%
Revenue Growth (TTM YoY)
CAPLIPOINT has faster revenue growth
19% vs 2.3%
EPS Growth (TTM YoY)
CAPLIPOINT has faster EPS growth
19.4% vs -72.5%
Qtr Sales Growth
CAPLIPOINT has stronger quarterly sales growth
19.4% vs 2.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONCAPLIPOINT
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONCAPLIPOINT
Live Price₹436.4₹2,482.8
Day Change-0.89%-4.8%
Volume51.07 L1.64 L
52-Week High₹447.15₹2,699
52-Week Low₹331₹1,500.3
Distance from 52W High-2.4%-8.01%

Valuation

MetricBIOCONCAPLIPOINT
Market Cap₹70,989 Cr₹18,839 Cr
P/E Ratio185.25x31.01x
P/B Ratio2.1x5.54x
EPS₹2.86₹83.98
Book Value₹210.14₹462.02
Dividend Yield0.11%0.3%

Growth

MetricBIOCONCAPLIPOINT
Revenue Growth (TTM YoY)2.3%19%
EPS Growth (TTM YoY)-72.5%19.4%
Qtr Sales Growth2.25%19.4%
Qtr Profit Growth-62%19.3%

Profitability & Leverage

MetricBIOCONCAPLIPOINT
ROE1.4%20.6%
ROCE3.75%24.6%
Net Margin2.29%29.2%
Operating Margin20.4%34.8%
Debt to Equity0.45x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONCAPLIPOINT
Promoter Holding29.73% 0.17 pp70.57%
FII Holding8.16% 0.64 pp6.15% 0.44 pp
DII Holding23.37% 0.7 pp2.14% 0.09 pp
Public Holding23.74% 0.33 pp21.14% 0.35 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biocon Limited and Caplin Point Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.